No Data
No Data
No Data
No Data
No Data
Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM
Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM
Dow JonesMar 26 08:01 ET
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced s
GlobeNewswireMar 26 08:00 ET
Ayala Completes Patient Enrollment for Pivotal Desmoid Tumor Study
Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, has announced the completion of patient enrollment for its Phase 3 RINGSIDE study, which is evaluating the efficacy of the drug AL102 in treating desmoid tumors.
Investing.com Feb 20 10:32 ET
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment h
GlobeNewswireFeb 20 08:00 ET
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating.
MT NewswiresFeb 7 08:53 ET
Advaxis Announces Definitive Agreement With Ayala Pharmaceuticals
TipRanksFeb 7 04:17 ET
win wang wang : Really ah? Omg
No Data
No Data